Where can I learn more about this study?
You can find more information about this study on the websites listed below. If
more information about the study results is available, it can also be found here.
X www.clinicaltrials.gov. Once you are on the website, type “NCT02551159”
into the search box and click “Search”.
X www.clinicaltrialsregister.eu. Once you are on the website, click “Home and
Search”, then type “2015-003589-10” in the search box and click “Search”.
X www.AstraZenecaClinicalTrials.com. Once you are on the website, type
“D419LC00001” into the search box, and click “Find a Study”.
Full Study Title: A Phase III Randomized, Open-label, Multi-center, Global Study
of Durvalumab Alone or in Combination with Tremelimumab versus Standard of
Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and
Neck Cancer Patients – (KESTREL)
AstraZeneca Protocol Number: D419LC00001
National Clinical Trials Number: NCT02551159
AstraZeneca sponsored this study and has its headquarters at Cambridge, UK.
The phone number for the AstraZeneca Information Center is +1-877-240-9479.
Thank you
Clinical study participants and their families belong to a large community of
people who take part in clinical research around the world. They help researchers
answer important health questions and find medical treatments for patients.
The Center for Information & Study on Clinical Research Participation (CISCRP) is a non-profit organization
focused on educating and informing the public about clinical research participation. CISCRP is not
involved in recruiting participants for clinical studies, nor is it involved in conducting clinical studies.
CISCRP | One Liberty Square, Suite 1100 • Boston, MA 02109 | 1-877-MED-HERO | www.ciscrp.org
Version 1.0 2021_09_16
16 | Clinical Study Results